Erythropoietin in Continuous Ambulatory Peritoneal Dialysis: Experience with Subcutaneous Administration

Experience in the use of subcutaneous erythropoietin (EPO) in 32 continuous ambulatory peritoneal dialysis (CAPD) patients is presented. All patients were treated with oral iron supplements. The total and mean I SD durations of EPO treatment were 466 weeks and 14.6±10.1 weeks respectively. Twenty -two patients started treatment with normal or elevated iron stores; 10 had an initial iron saturation <20%. The initial hematocrit was 23.8±3.7%. Thirteen patients reached a steady -state hematocrit by the end of the study period, when the mean I SD hematocrit for all32 patients was 34.1±3.6%. All patients responded to EPO. The initial dose of EPO was 147.1 ± 53.8 U/kg/week. Maintenance dose was 72±36 U/kg/week.